195 related articles for article (PubMed ID: 16388022)
1. Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis.
Goncharova EA; Goncharov DA; Lim PN; Noonan D; Krymskaya VP
Am J Respir Cell Mol Biol; 2006 Apr; 34(4):473-80. PubMed ID: 16388022
[TBL] [Abstract][Full Text] [Related]
2. Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.
Goncharova EA; Goncharov DA; Spaits M; Noonan DJ; Talovskaya E; Eszterhas A; Krymskaya VP
Am J Respir Cell Mol Biol; 2006 May; 34(5):561-72. PubMed ID: 16424383
[TBL] [Abstract][Full Text] [Related]
3. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
Makovski V; Haklai R; Kloog Y
Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
[TBL] [Abstract][Full Text] [Related]
4. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
[TBL] [Abstract][Full Text] [Related]
5. Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.
Krymskaya VP
Proc Am Thorac Soc; 2008 Jan; 5(1):119-26. PubMed ID: 18094094
[TBL] [Abstract][Full Text] [Related]
6. TSC2 modulates cell adhesion and migration via integrin-α1β1.
Moir LM; Black JL; Krymskaya VP
Am J Physiol Lung Cell Mol Physiol; 2012 Oct; 303(8):L703-10. PubMed ID: 22923640
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.
Steagall WK; Pacheco-Rodriguez G; Glasgow CG; Ikeda Y; Lin JP; Zheng G; Moss J
Am J Pathol; 2013 Sep; 183(3):938-50. PubMed ID: 23867796
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2.
Goldberg AA; Joung KB; Mansuri A; Kang Y; Echavarria R; Nikolajev L; Sun Y; Yu JJ; Laporte SA; Schwertani A; Kristof AS
Oncotarget; 2016 Sep; 7(38):61152-61165. PubMed ID: 27458154
[TBL] [Abstract][Full Text] [Related]
9. Human Pluripotent Stem Cell-Derived
Julian LM; Delaney SP; Wang Y; Goldberg AA; Doré C; Yockell-Lelièvre J; Tam RY; Giannikou K; McMurray F; Shoichet MS; Harper ME; Henske EP; Kwiatkowski DJ; Darling TN; Moss J; Kristof AS; Stanford WL
Cancer Res; 2017 Oct; 77(20):5491-5502. PubMed ID: 28830860
[TBL] [Abstract][Full Text] [Related]
10. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
[TBL] [Abstract][Full Text] [Related]
11. Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis.
Goncharova EA; Goncharov DA; Damera G; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
Mol Pharmacol; 2009 Oct; 76(4):766-77. PubMed ID: 19596836
[TBL] [Abstract][Full Text] [Related]
12. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis.
Pacheco-Rodriguez G; Steagall WK; Crooks DM; Stevens LA; Hashimoto H; Li S; Wang JA; Darling TN; Moss J
Cancer Res; 2007 Nov; 67(21):10573-81. PubMed ID: 17975002
[TBL] [Abstract][Full Text] [Related]
13. Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.
Prizant H; Taya M; Lerman I; Light A; Sen A; Mitra S; Foster TH; Hammes SR
Endocr Relat Cancer; 2016 Apr; 23(4):265-80. PubMed ID: 26880751
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
15. TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase.
Goncharova E; Goncharov D; Noonan D; Krymskaya VP
J Cell Biol; 2004 Dec; 167(6):1171-82. PubMed ID: 15611338
[TBL] [Abstract][Full Text] [Related]
16. SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis.
Tyryshkin A; Bhattacharya A; Eissa NT
Cancer Res; 2014 Apr; 74(7):1996-2005. PubMed ID: 24691995
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
18. TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival.
Lesma E; Ancona S; Sirchia SM; Orpianesi E; Grande V; Colapietro P; Chiaramonte E; Di Giulio AM; Gorio A
J Cell Mol Med; 2014 May; 18(5):766-79. PubMed ID: 24606538
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular insights into lymphangioleiomyomatosis.
Steagall WK; Taveira-DaSilva AM; Moss J
Sarcoidosis Vasc Diffuse Lung Dis; 2005 Dec; 22 Suppl 1():S49-66. PubMed ID: 16457017
[TBL] [Abstract][Full Text] [Related]
20. Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM.
Lesma E; Grande V; Ancona S; Carelli S; Di Giulio AM; Gorio A
PLoS One; 2008; 3(10):e3558. PubMed ID: 18958173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
